Association/NN
Analysis/NN
of/IN
TEC/NNS
Polymorphisms/NNS
with/IN
Aspirin-Exacerbated/JJ
Respiratory/JJ
Disease/NN
in/IN
a/DT
Korean/JJ
Population/NN
./.
====================
The/DT
tyrosine-protein/JJ
kinase/NN
Tec/JJ
(/(
TEC/NNS
)/)
is/VBZ
a/DT
member/NN
of/IN
non-receptor/JJ
tyrosine/NN
kinases/NNS
and/CC
has/VBZ
critical/JJ
roles/NNS
in/IN
cell/NN
signaling/NN
transmission/NN
,/,
calcium/NN
mobilization/NN
,/,
gene/NN
expression/NN
,/,
and/CC
transformation/NN
./.
====================
TEC/NNS
is/VBZ
also/RB
involved/VBN
in/IN
various/JJ
immune/JJ
responses/NNS
,/,
such/JJ
as/IN
mast/NN
cell/NN
activation/NN
./.
====================
Therefore/RB
,/,
we/PRP
hypothesized/VBD
that/IN
TEC/NNS
polymorphisms/NNS
might/MD
be/VB
involved/VBN
in/IN
aspirin-exacerbated/JJ
respiratory/JJ
disease/NN
(/(
AERD/NN
)/)
pathogenesis/NN
./.
====================
We/PRP
genotyped/VBD
38/CD
TEC/NNS
single/JJ
nucleotide/NN
polymorphisms/NNS
in/IN
a/DT
total/JJ
of/IN
592/CD
subjects/NNS
,/,
which/WDT
comprised/VBD
163/CD
AERD/NN
cases/NNS
and/CC
429/CD
aspirin-tolerant/JJ
asthma/NN
controls/VBZ
./.
====================
Logistic/JJ
regression/NN
analysis/NN
was/VBD
performed/VBN
to/TO
examine/VB
the/DT
associations/NNS
between/IN
TEC/NNS
polymorphisms/NNS
and/CC
the/DT
risk/NN
of/IN
AERD/NN
in/IN
a/DT
Korean/JJ
population/NN
./.
====================
The/DT
results/NNS
revealed/VBD
that/IN
TEC/NNS
polymorphisms/NNS
and/CC
major/JJ
haplotypes/NNS
were/VBD
not/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
AERD/NN
./.
====================
In/IN
another/DT
regression/NN
analysis/NN
for/IN
the/DT
fall/JJ
rate/NN
of/IN
forced/JJ
expiratory/JJ
volume/NN
in/IN
1/CD
second/JJ
(/(
FEV1/NN
)/)
by/IN
aspirin/NN
provocation/NN
,/,
two/CD
variations/NNS
(/(
rs7664091/NN
and/CC
rs12500534/NN
)/)
and/CC
one/CD
haplotype/NN
(/(
TEC_BL2_ht4/NN
)/)
showed/VBD
nominal/JJ
associations/NNS
with/IN
FEV1/NN
decline/VBP
(/(
p/NN
=/JJ
0.03-0.04/CD
)/)
./.
====================
However/RB
,/,
the/DT
association/NN
signals/NNS
were/VBD
not/RB
retained/VBN
after/IN
performing/VBG
corrections/NNS
for/IN
multiple/JJ
testing/VBG
./.
====================
Despite/IN
TEC/NNS
playing/VBG
an/DT
important/JJ
role/NN
in/IN
immune/JJ
responses/NNS
,/,
the/DT
results/NNS
from/IN
the/DT
present/JJ
study/NN
suggest/VBP
that/IN
TEC/NNS
polymorphisms/NNS
do/VBP
not/RB
affect/VB
AERD/NN
susceptibility/NN
./.
====================
Findings/NNS
from/IN
the/DT
present/JJ
study/NN
might/MD
contribute/VB
to/TO
the/DT
genetic/JJ
etiology/NN
of/IN
AERD/NN
pathogenesis/NN
./.
====================
Asthma/NN
is/VBZ
a/DT
disease/NN
that/DT
is/VBZ
caused/VBN
by/IN
inflammation/NN
in/IN
the/DT
lung/NN
and/CC
bronchus/RB
and/CC
is/VBZ
affected/VBN
by/IN
genetic/JJ
and/CC
environmental/JJ
influences/VBZ
./.
====================
Aspirin-exacerbated/JJ
respiratory/JJ
disease/NN
(/(
AERD/NN
)/)
,/,
which/WDT
was/VBD
first/JJ
reported/VBD
in/IN
1922/CD
,/,
is/VBZ
a/DT
type/NN
of/IN
asthma/NN
./.
====================
AERD/DT
is/VBZ
characterized/VBN
by/IN
the/DT
following/VBG
three/CD
symptoms/NNS
:/:
bronchial/JJ
asthma/NN
,/,
aspirin/NN
sensitivity/NN
,/,
and/CC
nasal/JJ
polyposis/NN
[/(
1/CD
,/,
2/CD
,/,
3/CD
]/)
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
10-20/CD
%/NN
of/IN
asthma/NN
patients/NNS
have/VBP
aspirin/NN
sensitivity/NN
,/,
whereas/IN
1-2/CD
%/NN
of/IN
the/DT
non-asthma/NN
population/NN
shows/VBZ
aspirin/NN
sensitivity/NN
[/(
4/CD
,/,
5/CD
]/)
./.
====================
Although/IN
the/DT
mechanisms/NNS
of/IN
AERD/NN
pathogenesis/NN
are/VBP
still/RB
not/RB
fully/RB
understood/VBN
,/,
inflammatory/JJ
responses/NNS
by/IN
overproduction/NN
of/IN
leukotrienes/NNS
are/VBP
regarded/VBN
as/IN
the/DT
main/JJ
pathogenesis/NN
of/IN
AERD/NN
./.
====================
Aspirin/NN
is/VBZ
a/DT
commonly/RB
used/VBN
medication/NN
,/,
which/WDT
belongs/VBZ
to/TO
the/DT
non-steroidal/JJ
anti-inflammatory/JJ
drugs/NNS
./.
====================
Despite/IN
being/VBG
a/DT
widely/RB
used/VBN
medication/NN
,/,
aspirin/NN
intake/JJ
also/RB
causes/VBZ
various/JJ
side/JJ
effects/NNS
,/,
including/VBG
manifested/VBN
gastrointestinal/JJ
ulcer/JJ
,/,
stomach/NN
bleeding/VBG
,/,
and/CC
tinnitus/JJ
,/,
especially/RB
in/IN
higher/JJR
doses/NNS
./.
====================
Although/IN
the/DT
side/JJ
effects/NNS
of/IN
aspirin/NN
are/VBP
not/RB
common/JJ
,/,
these/DT
effects/NNS
have/VBP
been/VBN
reported/VBN
in/IN
about/RB
10/CD
%/NN
of/IN
adult/JJ
asthmatics/NNS
./.
====================
In/IN
AERD/NN
pathogenesis/NN
,/,
aspirin/NN
inhibits/VBZ
the/DT
activation/NN
of/IN
cyclooxygenase-1/NN
enzyme/NN
,/,
leading/VBG
to/TO
block/VB
of/IN
production/NN
of/IN
prostaglandin/NN
and/CC
thromboxane/NN
./.
====================
This/DT
mechanism/NN
causes/VBZ
overproduction/NN
of/IN
leukotrienes/NNS
,/,
such/JJ
as/IN
leukotriene/NN
B4/NN
,/,
leukotriene/NN
C4/NN
,/,
leukotriene/NN
D4/NN
,/,
and/CC
leukotriene/NN
E4/NN
[/(
6/CD
,/,
7/CD
]/)
./.
====================
The/DT
tyrosine-protein/JJ
kinase/NN
Tec/JJ
(/(
TEC/NNS
)/)
is/VBZ
a/DT
member/NN
of/IN
the/DT
non-receptor/JJ
tyrosine/NN
kinases/NNS
and/CC
has/VBZ
critical/JJ
roles/NNS
in/IN
cell/NN
signaling/NN
transmission/NN
,/,
calcium/NN
mobilization/NN
,/,
gene/NN
expression/NN
,/,
and/CC
transformation/NN
[/(
8/CD
]/)
./.
====================
It/PRP
has/VBZ
been/VBN
known/VBN
that/IN
TEC/NNS
family/NN
kinases/NNS
are/VBP
associated/VBN
with/IN
various/JJ
intracellular/JJ
signaling/VBG
mechanisms/NNS
,/,
such/JJ
as/IN
cytokine/NN
receptors/NNS
and/CC
lymphocyte/NN
surface/NN
antigens/NNS
[/(
9/CD
,/,
10/CD
]/)
./.
====================
In/IN
particular/JJ
,/,
it/PRP
was/VBD
demonstrated/VBN
that/IN
the/DT
TEC/NNS
family/NN
proteins/NNS
are/VBP
involved/VBN
in/IN
regulation/NN
of/IN
leukotriene/NN
secretion/NN
via/IN
the/DT
mast/NN
cell/NN
signaling/NN
pathway/NN
[/(
11/CD
]/)
./.
====================
Therefore/RB
,/,
we/PRP
hypothesized/VBD
that/IN
TEC/NNS
polymorphisms/NNS
might/MD
be/VB
involved/VBN
in/IN
AERD/NN
pathogenesis/NN
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
38/CD
TEC/NNS
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
were/VBD
genotyped/VBN
in/IN
a/DT
total/JJ
of/IN
592/CD
subjects/NNS
,/,
which/WDT
comprised/VBD
163/CD
AERD/NN
cases/NNS
and/CC
429/CD
aspirin-tolerant/JJ
asthma/NN
(/(
ATA/NN
)/)
controls/VBZ
,/,
to/TO
examine/VB
the/DT
associations/NNS
between/IN
TEC/NNS
polymorphisms/NNS
and/CC
AERD/NN
susceptibility/NN
./.
====================
Study/NN
subjects/NNS
====================
Subjects/NNS
in/IN
this/DT
study/NN
were/VBD
recruited/VBN
from/IN
the/DT
Asthma/NN
Genome/NN
Research/NN
Center/NN
,/,
comprising/VBG
the/DT
hospitals/NNS
of/IN
Soonchunhyang/JJ
,/,
Chunnam/JJ
,/,
Chungbuk/NNP
,/,
Seoul/JJ
National/JJ
,/,
and/CC
Chung-Ang/JJ
Universities/NNS
in/IN
Korea/NN
./.
====================
All/DT
subjects/NNS
provided/VBD
written/CD
informed/VBN
consents/NNS
,/,
and/CC
the/DT
study/NN
protocols/NNS
were/VBD
approved/VBN
by/IN
the/DT
institutional/JJ
review/NN
board/JJ
of/IN
each/DT
hospital/JJ
./.
====================
Diagnosis/NN
of/IN
AERD/NN
was/VBD
performed/VBN
according/VBG
to/TO
a/DT
modified/JJ
method/NN
as/IN
previously/RB
described/VBN
[/(
12/CD
]/)
./.
====================
We/PRP
also/RB
performed/VBN
aspirin/NN
challenge/NN
in/IN
subjects/NNS
with/IN
a/DT
history/JJ
of/IN
aspirin/NN
hypersensitivity/NN
,/,
presence/NN
of/IN
urticaria/NN
,/,
nasal/JJ
polyp/NN
,/,
and/CC
sinusitis/NN
./.
====================
The/DT
AERD/NN
case/NN
group/NN
included/VBD
patients/NNS
with/IN
20/CD
%/NN
or/CC
greater/JJR
decreases/VBZ
in/IN
forced/JJ
expiratory/JJ
volume/NN
in/IN
1/CD
second/JJ
(/(
FEV1/NN
)/)
or/CC
15/CD
%/NN
to/TO
19/CD
%/NN
decreases/VBZ
in/IN
FEV1/NN
with/IN
naso-ocular/JJ
or/CC
cutaneous/JJ
reactions/NNS
,/,
whereas/IN
subjects/NNS
showing/VBG
a/DT
rate/NN
of/IN
FEV1/NN
decline/VBP
less/RBR
than/IN
15/CD
%/NN
without/IN
extrabronchial/JJ
nasal/JJ
or/CC
skin/NN
symptoms/NNS
were/VBD
included/VBN
in/IN
the/DT
ATA/NN
group/NN
./.
====================
The/DT
clinical/JJ
diagnostic/JJ
factors/NNS
for/IN
the/DT
present/JJ
study/NN
are/VBP
summarized/VBN
in/IN
Table/JJ
1/CD
./.
====================
SNP/NN
selection/NN
and/CC
genotyping/VBG
====================
To/TO
investigate/VB
the/DT
associations/NNS
between/IN
TEC/NNS
polymorphisms/NNS
and/CC
the/DT
risk/NN
of/IN
AERD/NN
,/,
we/PRP
selected/VBD
candidate/NN
SNPs/NNS
based/VBN
on/IN
allele/NN
frequencies/NNS
in/IN
the/DT
Asian/JJ
population/NN
,/,
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
status/NN
,/,
and/CC
National/JJ
Center/NN
for/IN
Biotechnology/NN
information/NN
./.
====================
The/DT
data/NNS
for/IN
selection/NN
were/VBD
obtained/VBN
from/IN
the/DT
International/JJ
HapMap/NN
database/NN
(/(
http/NN
:/:
//hapmap.ncbi.nlm.nih.gov//JJ
)/)
./.
====================
Genotyping/VBG
of/IN
38/CD
TEC/NNS
polymorphisms/NNS
was/VBD
performed/VBN
in/IN
a/DT
total/JJ
of/IN
592/CD
subjects/NNS
,/,
including/VBG
163/CD
AERD/NN
cases/NNS
and/CC
429/CD
ATA/NN
controls/NNS
./.
====================
Genotyping/VBG
was/VBD
carried/VBN
out/RP
with/IN
20/CD
ng/NN
of/IN
genomic/JJ
DNA/NN
by/IN
TaqMan/NN
assay/NN
using/VBG
ABI/NN
prism/NN
7900HT/CD
sequence/NN
detection/NN
system/NN
software/RB
version/NN
2.3/CD
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
in/IN
all/DT
subjects/NNS
./.
====================
Assay/NN
IDs/NNS
of/IN
all/DT
SNPs/NNS
used/VBN
in/IN
TaqMan/NN
assay/NN
are/VBP
listed/VBN
in/IN
Supplementary/JJ
Table/JJ
1/CD
./.
====================
Statistics/NNS
====================
We/PRP
applied/VBD
a/DT
widely/RB
used/VBN
measure/VB
of/IN
linkage/NN
disequilibrium/NN
to/TO
all/DT
pairs/NNS
of/IN
biallelic/JJ
loci/NNS
:/:
Lewontin/NN
's/POS
D/NN
'/``
(/(
|D'|/NNP
)/)
[/(
13/CD
]/)
and/CC
r2/NN
./.
====================
Haplotypes/NNS
of/IN
each/DT
individual/JJ
were/VBD
inferred/VBN
using/VBG
the/DT
PHASE/NN
algorithm/NN
(/(
ver/RB
./.
====================
2.0/CD
)/)
,/,
developed/VBD
by/IN
Stephens/NNS
et/FW
al/JJ
./.
====================
[/(
14/CD
]/)
./.
====================
Linear/JJ
regression/NN
analysis/NN
was/VBD
performed/VBN
to/TO
examine/VB
the/DT
differences/NNS
in/IN
the/DT
rates/NNS
of/IN
decline/NN
in/IN
FEV1/NN
following/VBG
aspirin/NN
challenge/NN
among/IN
the/DT
genotypes/NNS
and/CC
major/JJ
haplotypes/NNS
./.
====================
The/DT
data/NNS
were/VBD
managed/VBN
and/CC
analyzed/VBD
using/VBG
Statistical/JJ
Analysis/NN
System/NN
,/,
version/NN
9.2/CD
(/(
SAS/NN
Inc./NNP
,/,
Cary/NN
,/,
NC/NN
,/,
USA/NN
)/)
./.
====================
Associations/NNS
for/IN
AERD/NN
under/IN
the/DT
logistic/JJ
model/NN
were/VBD
adjusted/VBN
by/IN
smoking/VBG
status/NN
,/,
atopy/NN
,/,
body/NN
mass/NN
index/NN
(/(
BMI/NN
)/)
,/,
age/NN
,/,
and/CC
sex/NN
(/(
male/JJ
=/JJ
0/CD
,/,
female/JJ
=/JJ
1/CD
)/)
./.
====================
Significant/JJ
associations/NNS
are/VBP
shown/VBN
in/IN
boldface/NN
(/(
p/NN
</JJR
0.05/CD
)/)
./.
====================
We/PRP
recruited/VBD
a/DT
total/JJ
of/IN
592/CD
subjects/NNS
,/,
which/WDT
consisted/VBD
of/IN
163/CD
AERD/NN
cases/NNS
and/CC
429/CD
ATA/NN
controls/NNS
,/,
for/IN
the/DT
present/JJ
study/NN
./.
====================
According/VBG
to/TO
the/DT
results/NNS
,/,
four/CD
clinical/JJ
characteristics/NNS
showed/VBD
significant/JJ
differences/NNS
between/IN
the/DT
case/NN
and/CC
control/NN
groups/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
The/DT
fall/JJ
rate/NN
by/IN
aspirin/NN
provocation/NN
was/VBD
significantly/RB
higher/JJR
in/IN
AERD/NN
subjects/NNS
than/IN
ATA/NN
controls/NNS
(/(
24.63/CD
±/CD
16.11/CD
vs./CC
3.54/CD
±/CD
4.85/CD
;/:
p/NN
=/JJ
0.0001/CD
)/)
./.
====================
Percentage/NN
of/IN
predicted/VBN
FEV1/NN
in/IN
the/DT
AERD/NN
subjects/NNS
showed/VBD
decreased/VBN
lung/NN
function/NN
than/IN
in/IN
ATA/NN
subjects/NNS
(/(
87.58/CD
±/CD
16.94/CD
vs./CC
91.66/CD
±/CD
16.87/CD
;/:
p/NN
=/JJ
0.009/CD
)/)
./.
====================
Also/RB
,/,
age/NN
of/IN
first/JJ
medical/JJ
examination/NN
and/CC
BMI/NN
were/VBD
lower/JJR
in/IN
AERD/NN
cases/NNS
than/IN
ATA/NN
controls/NNS
./.
====================
The/DT
other/JJ
diagnostic/JJ
factors/NNS
showed/VBD
no/DT
significant/JJ
differences/NNS
between/IN
the/DT
case/NN
and/CC
control/NN
group/NN
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
38/CD
TEC/NNS
polymorphisms/NNS
and/CC
12/CD
major/JJ
haplotypes/NNS
were/VBD
used/VBN
for/IN
the/DT
association/NN
analyses/NNS
./.
====================
Locations/NNS
of/IN
the/DT
polymorphisms/NNS
are/VBP
shown/VBN
in/IN
a/DT
genetic/JJ
map/VBP
of/IN
TEC/NNS
with/IN
their/PRP$
LD/NN
status/NN
(/(
Fig/NN
./.
====================
1A/NN
)/)
./.
====================
Minor/CC
allele/NN
frequencies/NNS
(/(
MAFs/NNS
)/)
of/IN
the/DT
SNPs/NNS
in/IN
Korean/JJ
subjects/NNS
are/VBP
displayed/VBN
in/IN
Supplementary/JJ
Table/JJ
2/CD
with/IN
their/PRP$
allele/NN
change/NN
,/,
position/NN
,/,
and/CC
p-value/JJ
for/IN
Hardy-Weinberg/JJ
equilibrium/NN
./.
====================
All/DT
SNPs/NNS
were/VBD
in/IN
Hardy-Weinberg/JJ
equilibrium/NN
./.
====================
The/DT
LD/NN
blocks/VBZ
were/VBD
obtained/VBN
by/IN
using/VBG
HaploView/NN
software/JJ
,/,
and/CC
the/DT
haplotypes/NNS
of/IN
each/DT
LD/NN
block/VBP
were/VBD
calculated/VBN
by/IN
PHASE/NN
software/JJ
(/(
Fig/NN
./.
====================
1B/NN
and/CC
1C/NN
)/)
./.
====================
We/PRP
used/VBD
major/JJ
haplotypes/NNS
that/WDT
had/VBD
frequencies/NNS
higher/JJR
than/IN
0.05/CD
for/IN
further/JJ
analyses/NNS
./.
====================
The/DT
minor/JJ
haplotypes/NNS
that/WDT
had/VBD
frequencies/NNS
lower/JJR
than/IN
0.05/CD
were/VBD
merged/VBN
and/CC
presented/VBN
as/IN
'Others/NNS
./.
'/``
====================
To/TO
compare/VB
genetic/JJ
differences/NNS
among/IN
ethnicities/NNS
,/,
we/PRP
obtained/VBD
MAFs/NNS
of/IN
Caucasians/NNS
,/,
Han/NNP
Chinese/JJ
,/,
Japanese/JJ
,/,
and/CC
Africans/NNS
from/IN
the/DT
NCBI/NN
database/NN
(/(
dbSNP/NN
)/)
(/(
Supplementary/JJ
Table/JJ
2/CD
)/)
and/CC
calculated/VBN
LD/NN
blocks/VBZ
using/VBG
genotype/JJ
data/NNS
from/IN
the/DT
International/JJ
HapMap/NN
database/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
./.
====================
As/IN
a/DT
result/NN
,/,
Asian/JJ
populations/NNS
showed/VBD
similar/JJ
MAFs/NNS
,/,
whereas/IN
the/DT
other/JJ
populations/NNS
showed/VBD
distinct/JJ
differences/NNS
./.
====================
However/RB
,/,
we/PRP
did/VBD
not/RB
find/VB
any/DT
correlation/NN
in/IN
LD/NN
status/NN
in/IN
any/DT
ethnicity/NN
./.
====================
Logistic/JJ
analyses/NNS
were/VBD
performed/VBN
to/TO
investigate/VB
the/DT
associations/NNS
between/IN
TEC/NNS
polymorphisms/NNS
and/CC
the/DT
risk/NN
of/IN
AERD/NN
./.
====================
The/DT
result/NN
from/IN
analyses/NNS
revealed/VBD
that/IN
all/DT
SNPs/NNS
and/CC
major/JJ
haplotypes/NNS
were/VBD
not/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
AERD/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
two/CD
SNPs/NNS
(/(
rs7664091/CD
,/,
p/NN
=/JJ
0.04/CD
and/CC
rs12500534/NN
,/,
p/NN
=/JJ
0.03/CD
)/)
and/CC
one/CD
major/JJ
haplotype/NN
in/IN
LD/NN
block/VBP
2/CD
(/(
TEC_BL2_ht4/NN
,/,
p/NN
=/JJ
0.03/CD
)/)
showed/VBD
marginal/JJ
associations/NNS
in/IN
the/DT
regression/NN
analysis/NN
with/IN
the/DT
decline/NN
rate/NN
of/IN
FEV1/NN
(/(
Supplementary/JJ
Table/JJ
3/CD
)/)
./.
====================
However/RB
,/,
the/DT
association/NN
signals/NNS
of/IN
these/DT
polymorphisms/NNS
disappeared/VBN
after/IN
performing/VBG
corrections/NNS
for/IN
multiple/JJ
testing/VBG
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
Taken/VBN
together/RB
,/,
these/DT
results/NNS
indicate/VBP
that/IN
the/DT
TEC/NNS
polymorphisms/NNS
are/VBP
not/RB
associated/VBN
with/IN
AERD/NN
susceptibility/NN
,/,
at/IN
least/JJS
in/IN
the/DT
Korean/JJ
population/NN
./.
====================
The/DT
lack/NN
of/IN
associations/NNS
in/IN
this/DT
study/NN
suggests/VBZ
that/IN
although/IN
TEC/NNS
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
immune/JJ
responses/NNS
,/,
TEC/NNS
variants/NNS
do/VBP
not/RB
directly/RB
affect/VB
decreased/VBD
pulmonary/JJ
function/NN
by/IN
aspirin/NN
uptake/NN
./.
====================
However/RB
,/,
considering/VBG
the/DT
fact/NN
that/IN
the/DT
difference/NN
in/IN
frequency/NN
of/IN
polymorphisms/NNS
showed/VBD
different/JJ
effects/NNS
in/IN
various/JJ
populations/NNS
,/,
replication/NN
studies/NNS
in/IN
AERD/NN
subjects/NNS
in/IN
other/JJ
ethnicities/NNS
are/VBP
recommended/VBN
./.
====================
The/DT
present/JJ
study/NN
still/RB
had/VBD
several/JJ
limitations/NNS
./.
====================
First/RB
,/,
an/DT
average/NN
statistical/JJ
power/NN
of/IN
66.41/CD
%/NN
indicated/VBD
an/DT
insufficient/JJ
sample/NN
size/NN
./.
====================
However/RB
,/,
the/DT
rare/JJ
condition/NN
of/IN
AERD/NN
made/VBD
it/PRP
difficult/JJ
to/TO
recruit/VB
subjects/NNS
in/IN
the/DT
Korean/JJ
asthma/NN
cohort/NN
./.
====================
Second/RB
,/,
SNPs/NNS
in/IN
coding/VBG
sequence/NN
were/VBD
not/RB
selected/VBN
,/,
due/JJ
to/TO
very/RB
low/JJ
frequencies/NNS
,/,
although/IN
non-synonymous/JJ
SNPs/NNS
(/(
nsSNP/NN
)/)
in/IN
exonic/JJ
regions/NNS
could/MD
affect/VB
risk/NN
of/IN
the/DT
disease/NN
./.
====================
Further/RB
studies/NNS
are/VBP
required/VBN
to/TO
examine/VB
the/DT
molecular/JJ
role/NN
of/IN
nsSNPs/NNS
in/IN
TEC/NNS
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
hypothesized/VBD
that/IN
TEC/NNS
might/MD
impact/VB
on/IN
AERD/NN
susceptibility/NN
./.
====================
However/RB
,/,
our/PRP$
results/NNS
showed/VBD
that/IN
38/CD
TEC/NNS
polymorphisms/NNS
and/CC
12/CD
major/JJ
haplotypes/NNS
were/VBD
not/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
AERD/NN
./.
====================
Although/IN
further/JJ
studies/NNS
are/VBP
required/VBN
to/TO
investigate/VB
the/DT
exact/JJ
role/NN
of/IN
the/DT
TEC/NNS
SNPs/NNS
in/IN
immune/JJ
responses/NNS
,/,
the/DT
preliminary/JJ
results/NNS
of/IN
the/DT
present/JJ
study/NN
may/MD
provide/VB
useful/JJ
information/NN
for/IN
AERD/NN
pathogenesis/NN
./.
====================
Schematic/JJ
physical/JJ
map/NN
,/,
haplotypes/NNS
and/CC
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
plot/NN
of/IN
TEC/NNS
./.
====================
(/(
A/NN
)/)
Polymorphisms/NNS
identified/VBN
in/IN
TEC/NNS
./.
====================
Coding/VBG
exons/NNS
are/VBP
marked/JJ
by/IN
shaded/VBN
blocks/VBZ
and/CC
untranslated/JJ
region/NN
by/IN
white/JJ
blocks/VBZ
./.
====================
The/DT
LD/NN
coefficients/NNS
(/(
r2/NN
)/)
are/VBP
based/VBN
on/IN
the/DT
genotypes/NNS
of/IN
Korean/JJ
samples/NNS
./.
====================
(/(
B/NN
)/)
Haplotypes/NNS
are/VBP
calculated/VBN
using/VBG
genotypes/NNS
of/IN
TEC/NNS
polymorphisms/NNS
in/IN
a/DT
Korean/JJ
population/NN
./.
====================
Only/RB
those/DT
with/IN
frequencies/NNS
over/IN
0.05/CD
are/VBP
shown/VBN
in/IN
tables/NNS
./.
====================
Haplotypes/NNS
with/IN
frequencies/NNS
lower/JJR
than/IN
0.05/CD
are/VBP
merged/VBN
into/IN
``/NN
Others/NNS
./.
''/CD
====================
(/(
C/NN
)/)
LD/NN
coefficients/NNS
(/(
|D'|/NN
)/)
among/IN
the/DT
selected/VBN
SNPs/NNS
based/VBN
on/IN
the/DT
genotypes/NNS
of/IN
whole/JJ
study/NN
subjects/NNS
in/IN
this/DT
study/NN
./.
====================
Clinical/JJ
profile/NN
of/IN
subjects/NNS
in/IN
study/NN
with/IN
TEC/NNS
polymorphisms/NNS
====================
Association/NN
analysis/NN
of/IN
TEC/NNS
polymorphisms/NNS
and/CC
haplotypes/NNS
with/IN
the/DT
risk/NN
of/IN
AERD/NN
in/IN
a/DT
Korean/JJ
population/NN
====================
